Screener
BioMarin Pharmaceuticals BMRN Debt Issuance Proceeds
Debt Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfDebt.
The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:14 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001048477-26-000016
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Proceeds from exercises of awards under equity incentive plans | 6,655 | 7,707 |
| Taxes paid related to net share settlement of equity awards | (39,504) | (51,089) |
| Payments of contingent consideration | — | — |
| Proceeds from borrowings | 3,650,000 | — |
| Payments of debt issuance costs | (65,604) | — |
| Net cash provided by (used in) financing activities | 3,551,547 | (43,382) |
| Effect of exchange rate changes on cash | (1,630) | (4,479) |
| NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | (437,674) | 270,974 |
Item 1. Financial Statements
FAQ
- What is BioMarin Pharmaceuticals's debt issuance proceeds?
- BioMarin Pharmaceuticals (BMRN) reported debt issuance proceeds of $2.8B in Q2 2026.
- What does debt issuance proceeds mean?
- Cash received from issuing bonds, notes, term loans, and other debt instruments in the capital markets or from bank lending.
Ask your AI about BioMarin Pharmaceuticals's debt issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude